Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · March 14, 2024

Diagnostic Performance of 68Ga-RM2 PET–MRI vs MRI Alone in Patients With Biochemical Recurrence of Prostate Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Oncology
68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial
Lancet Oncol 2024 Feb 26;[EPub Ahead of Print], H Duan, F Moradi, GA Davidzon, T Liang, H Song, AM Loening, S Vasanawala, S Srinivas, JD Brooks, S Hancock, A Iagaru

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated